Loading stock data...

Concord Biotech Limited

NSE: CONCORDBIO BSE: CONCORDBIO

NSE
1,345.00 16.00 (1.20%)

Prev Close

1329

Open Price

1331.1

Volume

34,880

Today Low / High

1327 / 1348.9

52 WK Low / High

1314.9 / 2451.7

Range

1,278 - 1,412

BSE
1,340.20 12.85 (0.97%)

Prev Close

1327.35

Open Price

1327.4

Volume

2,133

Today Low / High

1327.4 / 1344.75

52 WK Low / High

1318.8 / 2451.65

Range

1,273 - 1,407

The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1345 (target range: 1,278 - 1,412), reflecting a change of 16 (1.20391%). On the BSE, it is listed at 1340.2 (target range: 1,273 - 1,407), showing a change of 12.85 (0.96809%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.

23 Dec 1,331.10 0.97%
22 Dec 1,346.70 -1.31%
19 Dec 1,348.90 -0.96%
18 Dec 1,328.10 1.19%
17 Dec 1,379.40 -3.49%
16 Dec 1,360.60 1.38%
15 Dec 1,375.10 -1.05%
12 Dec 1,371.00 -0.09%
11 Dec 1,380.00 -0.71%
10 Dec 1,375.00 0.44%
09 Dec 1,362.60 2.11%
08 Dec 1,408.40 -3.25%
05 Dec 1,402.50 0.42%
04 Dec 1,400.20 0.10%
03 Dec 1,431.00 -1.82%
02 Dec 1,433.00 0.32%
01 Dec 1,417.60 1.08%
30 Nov 1,417.60 1.08%
28 Nov 1,439.00 -1.49%
27 Nov 1,439.90 -0.76%
26 Nov 1,402.70 2.64%
25 Nov 1,429.80 -1.93%

Concord Biotech Limited Graph

Concord Biotech Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Concord Biotech Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,345.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 1,340.20 1,353.60 1,218.24 - 1,488.96
1,367.00 1,093.60 - 1,640.40
1,380.41 966.28 - 1,794.53
Bearish Scenario 1,340.20 1,326.80 1,194.12 - 1,459.48
1,313.40 1,050.72 - 1,576.08
1,299.99 910.00 - 1,689.99

Overview of Concord Biotech Limited

ISIN

INE338H01029

Industry

Biotechnology

Vol.Avg

93,271

Market Cap

140,708,794,380

Last Dividend

10.7

Official Website

Visit Website

IPO Date

2023-08-18

DCF Diff

922.74

DCF

421

Financial Ratios Every Investor Needs

Stock Dividend of CONCORDBIO

Date Label Adj Dividend Dividend Record Date Payment Date Declaration Date
2025-09-03 September 03, 25 10.7 10.7 2025-09-03 2025-10-09
2024-06-21 June 21, 24 8.75 8.75 2024-06-22 2024-07-29

Stock Rating Details for CONCORDBIO

Metric Value Recommendation
Overall Rating B+ Neutral
DCF Score 3 Neutral
ROE Score 4 Buy
ROA Score 5 Strong Buy
Debt-to-Equity (DE) Score 4 Buy
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 1,200.09 Cr 431.73 Cr 768.36 Cr 0.6403 27.44 Cr 0.00 Cr 601.99 Cr 371.64 Cr 35.52 512.71 Cr 0.3097
2024-03-31 1,016.94 Cr 349.75 Cr 667.19 Cr 0.6561 22.90 Cr 0.00 Cr 521.24 Cr 308.10 Cr 29.45 438.58 Cr 0.3030
2023-03-31 853.17 Cr 192.08 Cr 661.09 Cr 0.7749 32.83 Cr 0.00 Cr 517.97 Cr 240.09 Cr 22.95 352.65 Cr 0.2814
2022-03-31 712.93 Cr 171.92 Cr 541.02 Cr 0.7589 29.09 Cr 0.00 Cr 416.23 Cr 174.93 Cr 16.72 277.82 Cr 0.2454
2021-03-31 616.94 Cr 116.94 Cr 500.00 Cr 0.8105 0.00 Cr 0.00 Cr 430.04 Cr 234.89 Cr 22.45 328.71 Cr 0.3807

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 1.18 Cr 2,034.25 Cr 221.53 Cr 1,812.7175 Cr 2.97 Cr 1.79 Cr 239.67 Cr 844.22 Cr 0.00 Cr 0.00 Cr 39.29 Cr 184.0626 Cr
2024-03-31 15.14 Cr 1,700.71 Cr 174.06 Cr 1,526.6455 Cr 9.74 Cr -5.40 Cr 207.95 Cr 786.48 Cr 3.66 Cr 0.00 Cr -288.00 Cr 142.1554 Cr
2023-03-31 3.50 Cr 1,513.98 Cr 223.98 Cr 1,290.0010 Cr 31.55 Cr 28.05 Cr 212.32 Cr 765.48 Cr 0.00 Cr 0.00 Cr -168.12 Cr 191.8460 Cr
2022-03-31 0.67 Cr 1,312.80 Cr 209.57 Cr 1,103.2230 Cr 62.49 Cr 61.83 Cr 195.12 Cr 643.56 Cr 0.00 Cr 0.00 Cr -160.85 Cr 155.1680 Cr
2021-03-31 5.14 Cr 1,182.55 Cr 183.17 Cr 999.3730 Cr 89.28 Cr 84.14 Cr 153.61 Cr 557.75 Cr 0.00 Cr 0.00 Cr -195.70 Cr 105.7390 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 247.4104 Cr -162.9811 Cr -98.6669 Cr 136.2382 Cr -19.6343 Cr 1.1831 Cr -111.1722 Cr 371.6423 Cr -5.8487 Cr -91.5392 Cr -31.7134 Cr
2024-03-31 265.4671 Cr -154.6093 Cr -99.2149 Cr 179.7786 Cr 11.6429 Cr 15.1421 Cr -85.6885 Cr 308.1032 Cr -26.5036 Cr -71.4529 Cr 4.3609 Cr
2023-03-31 246.0018 Cr -157.9501 Cr -85.2194 Cr 100.9170 Cr 2.8323 Cr 3.4992 Cr -145.0848 Cr 240.0857 Cr -25.0000 Cr -53.5635 Cr -17.2273 Cr
2022-03-31 207.4750 Cr -111.7880 Cr -100.1640 Cr 51.9700 Cr -4.4770 Cr 0.6670 Cr -155.5050 Cr 174.9301 Cr -25.7630 Cr -70.5210 Cr -41.5090 Cr
2021-03-31 166.8170 Cr -195.2050 Cr 31.1240 Cr -37.3590 Cr 2.7360 Cr 5.1440 Cr -204.1760 Cr 234.8870 Cr 38.3210 Cr -5.7060 Cr -42.3770 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-09-30 247.06 Cr 49.02 Cr 198.04 Cr 0.8016 70.10 Cr 63.06 Cr 6.03 104.13 Cr 0.2553
2025-06-30 203.99 Cr 74.58 Cr 129.41 Cr 0.6344 91.51 Cr 44.06 Cr 4.21 57.21 Cr 0.2160
2025-03-31 429.88 Cr 171.82 Cr 258.07 Cr 0.6003 191.66 Cr 140.39 Cr 13.42 197.10 Cr 0.3266
2024-12-31 244.22 Cr 78.84 Cr 165.38 Cr 0.6772 130.74 Cr 75.92 Cr 7.26 97.65 Cr 0.3109
2024-09-30 310.18 Cr 76.32 Cr 233.86 Cr 0.7540 200.20 Cr 95.74 Cr 9.15 136.61 Cr 0.3087

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-09-30 17.29 Cr 364.11 Cr 381.39 Cr 396.79 Cr 276.28 Cr 1,079.84 Cr 862.27 Cr 2,023.22 Cr 196.41 Cr
2025-06-30 0.00 Cr 0.00 Cr 317.73 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -1,812.72 Cr
2025-03-31 1.18 Cr 316.54 Cr 317.73 Cr 521.65 Cr 239.67 Cr 1,135.24 Cr 844.22 Cr 2,034.25 Cr 221.53 Cr
2024-12-31 0.00 Cr 0.00 Cr 283.74 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -1,590.38 Cr
2024-09-30 8.46 Cr 275.28 Cr 283.74 Cr 344.45 Cr 250.42 Cr 934.65 Cr 806.03 Cr 1,764.34 Cr 173.97 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 44.06 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 140.39 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 75.92 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 95.74 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 59.59 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Biotechnology

Company Name Symbol Price Market Cap Volume
Biocon Limited BIOCON ₹400.90 ₹535,231,965,995.00 ₹1,907,146.00
Anthem Biosciences Ltd. ANTHEM ₹667.50 ₹374,874,709,043.00 ₹135,438.00
Syngene International Limited SYNGENE ₹657.00 ₹263,927,351,556.00 ₹188,342.00
Piramal Pharma Limited PPLPHARMA ₹177.85 ₹235,307,491,630.00 ₹3,267,295.00
Onesource Specialty Pharma Ltd. ONESOURCE ₹1,716.00 ₹196,588,615,080.00 ₹149,220.00
Concord Biotech Limited CONCORDBIO ₹1,345.00 ₹140,708,794,380.00 ₹34,880.00
Jubilant Ingrevia Limited JUBLINGREA ₹723.65 ₹114,317,031,193.00 ₹144,339.00
Blue Jet Healthcare Limited BLUEJET ₹549.80 ₹95,371,290,665.00 ₹235,213.00
Supriya Lifescience Limited SUPRIYA ₹751.90 ₹60,515,017,320.00 ₹67,558.00
Zota Health Care Limited ZOTA ₹1,565.10 ₹47,473,638,341.00 ₹64,186.00
Dishman Carbogen Amcis Limited DCAL ₹255.71 ₹40,091,005,222.00 ₹188,272.00

Key Executives

Joint MD, Chief Executive Officer & Executive Director
Ankur Vaid

Gender: male

Year Born: 1982

VP of Sales & Marketing and Head of Limbasi Plant-3
Devang Bhatt

Gender: male

Year Born:

Chief Financial Officer
Lalit Sethi

Gender: male

Year Born:

Vice President of Formulation Division & Head of Valthera Unit-2
Manoj Kumar

Gender: male

Year Born:

Assistant Vice President of Accounts & Finance
Prakash Lalchand Sajnani

Gender: male

Year Born:

Executive Chairman & MD
Sudhir Jairam Vaid

Gender: male

Year Born: 1952

Company Secretary & Compliance Officer
Hina Ronak Patel

Gender: female

Year Born:

General Manager, International Business Development
Sundeep Bengani

Gender: Not Specified

Year Born:

FAQs about Concord Biotech Limited

Who is the CEO of the company?

The CEO is Ankur Vaid.

What is the current market price of the stock?

The current price is ₹1,345.00.

What is the 52-week price range?

The range is ₹1314.9-2451.7.

What is the market capitalization of the company?

The market capitalization is ₹14,070.88 crores.

What is the dividend yield?

The dividend yield is 0.80%.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 43.49.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Concord Biotech Limited (ISIN: INE338H01029) is a leading Biotechnology in India. With a market capitalization of ₹14,070.88 crores and an average daily volume of 93,271 shares, it operates in the Biotechnology. The company last declared a dividend of ₹10.7.